Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.

Archives of toxicology - 1 May 2024

Kook Eunjin, Lee JungYeol, Kim Do-Hee

Abstract excerpt

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as gefitinib and osimertinib have primarily been used as first-line treatments for patients with EGFR-activating mutations in non-small cell lung cancer (NSCLC). Novel biomarkers are required to distinguish patients with lung cancer who are resistant to EGFR-TKIs. The aim of the study is to investigate the expression and functional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Dasatinib
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to NF-E2-Related Factor 2

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 38443724
DOI: 10.1007/s00204-024-03693-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.PMID 38443724Read ↗

Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.Semantic proximity Read ↗

Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.Semantic proximity Read ↗

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53Semantic proximity Read ↗

miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagySemantic proximity Read ↗

Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.Semantic proximity Read ↗

Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.Semantic proximity Read ↗

YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.